In 2006, about 235,000 Americans will be diagnosed with prostate cancer, making it the most common cancer among males. If caught early, prostate cancer is very treatable and usually curable.
There often are no signs of the disease, but some men may notice changes in urinary flow, pain when urinating and blood in the urine. At routine physicals, doctors usually take blood to check the level of prostate specific antigen (PSA). If the PSA level is high, the doctor will remove a small piece of prostate tissue to look for cancer.
For cancer that has not spread from the prostate, the main treatments are external beam radiation therapy, brachytherapy and surgery. Hormone therapy may be added to radiation therapy to stop the body from producing hormones that stimulate the growth of new cancer cells.
Here is an overview of the most common approaches.
• Surgery: A doctor operates to remove the cancerous prostate.
• Watchful waiting: For a very slow growing type of cancer, patients may be able to monitor their condition and not undergo any treatment. This option is for older men, or men who have other health conditions.
• Brachytherapy: Often called “seed implants,” this treatment involves placing radioactive sources in, or just next to the tumor to kill the cancer cells. The sources may be left in place permanently or temporarily, depending on the type of cancer and the seeds used.
• External beam radiation therapy: During this treatment, a radiation oncologist aims radiation at the tumor to destroy the cancer cells. At UCSD, two sophisticated forms of external beam radiotherapy are used – IMRT and IGRT. In IMRT, or Intensity Modulated Radiation Therapy, the radiation beam conforms precisely to the shape of the target, something like a shrink wrap, so adjacent healthy tissues are protected. For high-risk prostate cancer, IMRT is combined with hormonal therapy. In IGRT, or Image Guided Radiation Therapy, three to five marker seeds are placed in the prostate to pinpoint its location on daily basis. This technique takes into account daily organ movement, thereby improving the accuracy of treatment delivery and minimizing the exposure of adjacent healthy tissue. Better accuracy also enables the radiation dose to be safely increased, if needed. IGRT is not only used for treating the prostate, but also if radiation therapy is needed for any reason if the prostate was removed. In this situation, after a prostatectomy, surgical clips are visualized daily to pinpoint the target and the prostate bed. Treatments are painless, last about 30 minutes and are scheduled five days a week for several weeks. Most patients are able to continue their normal routines during radiation treatments.
Before undergoing any treatment, talk with several cancer specialists, including a radiation oncologist, about the options available.
The American Society for Therapeutic Radiology and Oncology offers a free brochure on prostate cancer. For a copy, visit
http://www.rtanswers.org .
Source: By Nancy Stringer, University of California, San Diego
Related stories:
Family history of prostate cancer does not affect some treatment outcomes
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the
International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.
New study shows that a cough medicine ingredient could effectively treat prostate cancer
A study published today in the December issue of the European medical journal
Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Researchers found that noscapine, which has been used in cough medication for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.
Hormone therapy for prostate cancer does not appear to increase cardiac deaths
Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths. In their
Journal of Clinical Oncology report, which has been released online, the researchers note that GnRH agonist treatment has a number of adverse side effects, which should be kept in mind when determining treatment strategies.
Cellular senescence a double-edged sword
Scientists have identified a molecular cause behind the ravages of old age and in doing so have also shown how a natural process for fighting cancer in younger persons can actually promote cancer in older individuals. Cellular senescence, the process by which biological cells stop dividing in response to stress or damage to their DNA, was shown to trigger the secretion of proteins that cause inflammation in neighboring cells and tissue. Inflammation is linked to almost every major disease associated with aging, including many cancers.
Genetic test can reveal a painful truth
Wanda Stutsman was 32 years old and seven months pregnant when she began her first round of chemotherapy.
Bevacizumab better than gold standard imaging at detecting tumors
Scientists have developed a new imaging agent that can be used in scanning for tumours, and which gives a much clearer and more precise image than existing methods. The discovery has the potential to revolutionise pre-clinical cancer research and clinical diagnostic practice, and it makes use of compounds that have already been approved for treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper nuclide, which is approved by the US Food and Drug Administration (FDA) for some clinical trials.
Study: When/if to start hormones for prostate cancer patients whose PSA rises after radiation
A new Fox Chase Cancer Center study suggests men with early stage prostate cancer treated with radiation therapy should begin hormone therapy immediately if their PSA level rises quickly and doubles within six months at any time after treatment. The study also supports foregoing hormones if the PSA doesn't rise as quickly. Both findings suggest a change in the practice of prescribing hormones is warranted.
Radiation added to hormone therapy increases survival for men with prostate cancer
For men with locally advanced prostate cancer the addition of radiation treatment to anti-androgen hormone therapy reduces the risk of dying of prostate cancer by 50 percent compared to those who have anti-androgen hormone treatment alone, according to a randomized study presented September 22, 2008, at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting in Boston.